Kashiwabara K, Matsuyama Y. Treatment effect estimation in an efficient adaptive design: comparison with the exact estimation method. 40th Annual Conference of the ISCB 2019, 14-18 July, Leuven, Belgium.
Satoi S, Unno M, Motoi F, Matsuyama Y, Matsumoto I, Aosasa S, Shirakawa H, Wada K, Fujii T, Yoshitomi H, Takahashi S, Sho M, Ueno H, Yamamoto H, Kosuge T. The effect of neoadjuvant chemotherapy with gemcitabine and S-1 for resectable pancreatic cancer (Randomized phase II/III trial; Prep-02/JSAP-05). ASCO 2019, May 31-June 4, Chicago, USA
Izumi N, Hasegawa K, Nishioka Y, Takayama T, Yamanaka N, Kudo M, Shimada M, Inomata M, Kaneko S, Baba H, Koike K, Omata M, Makuuchi M, Matsuyama Y, Kokudo N. A multicenter randomized controlled trial to evaluate the efficacy of surgery vs. radiofrequency ablation for small hepatocellular carcinoma (SURF trial). ASCO 2019, May 31-June 4, Chicago, USA. J Clin Oncol 37, 2019 (suppl; abstr 4002)
Matsumoto I, Unnno M, Motoi F, Satoi S, Aosasa S, Shirakawa H, Wada K, Matsuyama Y. The feasibility and efficacy of neoadjuvant chemotherapy for resectable pancreatic cancer: A randomized phase II/III trial from Japan. 48th World Congress of Surgery WCS 2019, Krakow, Poland, 14 August 2019.
Kobayashi K, Taira N, Sawaki M, Sagawa N, Baba S, Saito T, Kawahara T, Hagiwara Y, Uemura Y, Shimozuma K, Ohashi Y, Mukai H. Patient-reported outcomes with trastuzumab monotherapy versus trastuzumab plus standard chemotherapy as a postoperative adjuvant therapy in HER2-positive elderly breast cancer patients (RESPECT): A randomized, open-label, phase 3 clinical trial. San Antonio Breast Cancer Symposium 2018. San Antonio, the United States, December 2018.
Takahashi M, Sawaki M, Hagiwara Y, Uemura Y, Kawahara T, Shimozuma K, Ohashi Y, Saito T, Baba S, Kobayashi K, Mukai H, Taira N. Analysis of cognitive function in elderly HER2-positive breast cancer patients receiving either trastuzumab monotherapy or trastuzumab plus chemotherapy as a postoperative adjuvant treatment: A cognitive function sub-study of a randomized, open-label, phase 3 clinical trial (RESPECT trial). San Antonio Breast Cancer Symposium 2018. San Antonio, the United States, December 2018.
Kashiwabara K, Matsuyama Y. Point and interval estimation in an efficient adaptive design of flexible sample size determination. At: Joint International Society for Clinical Biostatistics and Australian Statistical Conference 2018, Melbourne, Australia, 26–30 August, 2018. Abstr P4.
Hagiwara Y, Taira N, Saito T, Baba S, Kobayashi K, Kawahara T, Shiroiwa T, Fukuda T, Shimozuma K, Uemura Y, Mukai H, Ohashi Y, Sawaki M. The EQ-5D index of elderly patients with HER-2 positive breast cancer: results from the randomized N-SAS BC 07 trial for adjuvant trastuzumab with and without chemotherapy. International Society for Pharmacoeconomics and Outcome Research Asia Pacific 2018 Conference. Tokyo, Japan. September 2018. PCN65.
Hagiwara Y, Shinozaki T, Matsuyama Y. G-estimation of structural nested restricted mean time lost models to estimate effect of time-varying treatment on survival outcome. 29th International Biometric Conference. Barcelona, Spain. July 2018. CS41.1.
Yoshino T, Yamanaka T, Denda T,Tsuji Y, Shinozaki K, Komatsu Y, Kobayashi Y, Furuse J, Okuda H, Asayama M, Akiyoshi K, Kagawa Y, Kato T, Oki E, Ando T, Hagiwara Y, Ohashi Y, Shitara K. REVERCE: randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecan: quality of life analysis. European Society for Medical Oncology World Congress on Gastrointestinal Cancer 2018. Barcelona, Spain. June 2018.
Tsuji Y, Shitara K, Yamanaka T, Denda T, Shinozaki K, Komatsu Y, Kobayashi Y, Furuse J, Okuda H,
Asayama M, Akiyoshi K, Kagawa Y, Kato T, Oki E, Ando T, Hagiwara Y, Ohashi Y, Yoshino T. REVERCE: randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence
for metastatic colorectal cancer patients previously treated With fluoropyrimidine, oxaliplatin, and irinotecan— biomarker analysis. American Society of Clinical Oncology Annual Meeting 2018, Chicago, US, June 3, 2018. Abstract 3510.
Karasaki T, Nagayama K, Kuwano H, Nitadori J, Sato M, Anraku M, Hosoi A, Matsushita H, Morishita Y, Kashiwabara K, Takazawa M, Ohara O, Kakimi K, Nakajima J. Immunogram for cancer-immunity cycle towards personalized immunotherapy of lung cancer. At: International Association for the Study of Lung Cancer, Chicago, IL. August 25–27, 2016. Abstr MA15.01.
Kashiwabara K, Matsuyama Y. A reasonable adaptive Simon’s two-stage design. At: 38th Annual Conference of the International Society for Clinical Biostatistics, Vigo, Spain, 9–13 July, 2017. Abstr PC2-M29.
Kashiwabara K, Matsuyama Y. An efficient adaptive sample size determination via working sequential designs for confirmatory clinical trials. At: 28th International Biometric Conference, Victoria, Canada, 10–15 July, 2016. Abstr 2465136.
Kashiwabara K, Matsuyama Y. Adaptive group sequential test without predetermination of total and group sample sizes. At: 2014 Joint Statistical Meetings, Boston, MA. August 2–7, 2014. Abstract 312721.